The alternative text for this image may have been generated using AI. Figure 2: Expression of CD30 in diploid or karyotypically abnormal hES cell lines. The alternative text for this image may have ...
Cells of certain blood cancers such as Hodgkin’s lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the ...
CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and ...
SINGAPORE, June 16, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and ...
Please provide your email address to receive an email when new articles are posted on . Since the discovery of the CD30 molecule in 1982, progress has been made in the treatment and survival outcomes ...
CD30 expression is characteristic of the malignant Reed-Sternberg cell in Hodgkin lymphoma (HL) and several other lymphoid malignancies, such as anaplastic large-cell lymphoma (ALCL). Although ...
A recent study explored the efficacy of brentuximab vedotin (BV) in patients with high-CD30–expressing non-Hodgkin lymphoma (NHL) to determine who is most likely to benefit. A recent study explored ...
Innovative CAR-T cell therapy achieves remarkable results in patients with refractory CD30+ lymphoma
Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...
SINGAPORE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and ...
The study, which was supported by the German Cancer Aid, suggests that vaccination against EBV might reduce the risk of developing Hodgkin's lymphoma. In addition, the study provides insights into new ...
High expression of CD30 and JunB is the hallmark of malignant cells in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). Ligand-independent signaling by CD30 induces JunB, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results